Results 51 to 60 of about 12,585 (215)

Gynecologic conditions in the context of incarceration: A scoping review

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 173, Issue 1, Page 117-137, April 2026.
Abstract Background More than 740 000 people identified as female at intake were incarcerated globally as of 2022, reflecting a 60% global increase since the year 2000, with a concomitant increase in gynecologic conditions experienced behind bars.
Meredith K. Wise   +6 more
wiley   +1 more source

Differentiated approach to the treatment of various forms of vulvovaginal candidiasis [PDF]

open access: yesГинекология, 2014
The article presents data on the results of examination and treatment of 55 patients with a diagnosis of «vulvovaginal candidiasis». In the study, the analysis of anamnestic data, and in addition, the clinical evaluation of vaginal discharge and the ...
T Yu Pestrikova   +4 more
doaj  

Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial [PDF]

open access: yes, 2017
BACKGROUND AND OBJECTIVE: Vulvovaginal candidiasis (VVC) is the most prevalent vaginitis in women, accounting for 10 million medical referrals a year. Vaginal clotrimazole is a drug of choice for VVC treatment. However, increased drug resistance to this
Banaeian-Borujeni, Shayesteh   +4 more
core   +1 more source

Recurrent Vulvovaginal Candidiasis

open access: yesBioscientia Medicina : Journal of Biomedicine and Translational Research, 2021
Vulvovaginal candidiasis is a common fungal infection caused by Candida Sp, especially Candida albicans. Recurrent vulvovaginal candidiasis was defined as the occurrence of four or more episodes of vulvovaginal candidiasis ​​in 12 months period. As many as 9% of women from various populations have recurrent vulvovaginal candidiasis.
Cyntya Sari Sovianti, null Mutia Devi
openaire   +2 more sources

Evidence‐ and consensus‐based guideline on lichen sclerosus

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 4, Page 566-584, April 2026.
Summary The German‐language, consensus‐ and evidence‐based S3 guideline on lichen sclerosus (LS) was developed based on the European “EuroGuiDerm Guideline on lichen sclerosus” under the leadership of the German Dermatological Society (DDG) and the German Society for Gynecology and Obstetrics (DGGG).
Gudula Kirtschig   +25 more
wiley   +1 more source

The epidemiology of Candida species isolated from urinary tract infections [PDF]

open access: yes, 2016
Candida spp. are members of a genus, including closely related fungal species that cause a variety of infections. Objectives: The aim of this study was the isolation of various Candida species from vulvovaginitis and urethra of patients in Neyshabur ...
Ang BS   +10 more
core   +1 more source

Evidenz‐ und konsensbasierte (S3) Leitlinie: Lichen sclerosus

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 4, Page 566-586, April 2026.
Zusammenfassung Die deutschsprachige, konsens‐ und evidenzbasierte S3‐Leitlinie zum Lichen sclerosus (LS) wurde unter Federführung der Deutschen Dermatologischen Gesellschaft e.V. (DDG) und der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e.V.
Gudula Kirtschig   +25 more
wiley   +1 more source

Investigating the relationship between recurrent vulvovaginal candidiasis with predisposing factors and symptoms of disease [PDF]

open access: yes, 2013
زمینه و هدف: ولوواژینیت کاندیدایی یک عفونت مخمری و از شایع ترین علل مراجعه زنان به پزشک می باشد. عوامل متعددی زمینه ساز ابتلا به این بیماری می شوند و در بعضی مطالعات گفته شده ریسک فاکتورها در ولوواژینیت عود کننده با غیر عود کننده متفاوت است.
Habibian, Roya   +2 more
core  

Candidiasis vulvovaginal recurrente

open access: yesRevista Medica Sinergia, 2021
La candidiasis vulvovaginal se presenta de manera frecuente en la vida de las mujeres, incluso se ha llegado a estimar que un 75% presentaran al menos un episodio en su vida. Se presenta sobre todo en mujeres en edad reproductiva, sin ser esta una infección de transmisión sexual, sin embargo, siempre debe realizarse un diagnóstico diferencial con otras
Fernanda Ugalde González   +2 more
openaire   +2 more sources

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page 617-625, April 2026.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy